HYFT
ImmunoPrecise Antibodies Ltd.
NASDAQ: HYFT · HEALTHCARE · BIOTECHNOLOGY
$1.19
+0.00% today
Updated 2026-04-30
Market cap
$54.19M
P/E ratio
—
P/S ratio
1.93x
EPS (TTM)
$-0.10
Dividend yield
—
52W range
$0 – $3
Volume
0.3M
ImmunoPrecise Antibodies Ltd. (HYFT) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | $1.76M | $1.90M | $2.72M | $5.47M | $11.15M | $14.72M | $17.91M | $19.80M | $21.17M | $24.81M | $24.31M |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | — | — | +7.5% | +43.5% | +101.0% | +103.9% | +32.0% | +21.7% | +10.6% | +6.9% | +17.2% | -2.0% |
| Cost of revenue | $7447.00 | $7447.00 | $3640.00 | $2812.00 | $3265.00 | $2679.00 | $2246.00 | $1263.00 | $1398.00 | $1042.00 | $823.00 | $1.98M | $6.76M | $13.04M | $15.30M | $6.51M | $10.63M | $13.85M | $15.62M | $12.81M |
| Gross profit | $-7447.00 | $-7447.00 | $-3640.00 | $-2812.00 | $-3265.00 | $-2679.00 | $-2246.00 | $-1263.00 | $-1398.00 | $-1042.00 | $-823.00 | $743763.00 | $-1.29M | $-1.89M | $-576292.00 | $11.40M | $9.17M | $7.32M | $9.19M | $11.50M |
| Gross margin | — | — | — | — | — | — | — | — | — | -0.1% | -0.0% | 27.3% | -23.6% | -16.9% | -3.9% | 63.7% | 46.3% | 34.6% | 37.1% | 47.3% |
| R&D | — | — | — | — | — | — | — | — | — | $621639.00 | $302769.00 | $683239.00 | $511836.00 | $495745.00 | $467292.00 | $1.86M | $7.84M | $12.58M | $4.09M | $4.90M |
| SG&A | — | — | — | $360918.00 | $255825.00 | $252614.00 | $205525.00 | $79901.00 | $94743.00 | $64835.00 | $997291.00 | $1.86M | $5.66M | $7.33M | $7.95M | $12.57M | $15.38M | $14.58M | $15.59M | $14.73M |
| Operating income | $-246477.00 | $-246477.00 | $-563996.00 | $-407682.00 | $-271172.00 | $-256946.00 | $-213337.00 | $-81920.00 | $-95394.00 | $-66033.00 | $-34431.00 | $-1.39M | $-4.80M | $-6.35M | $-4.29M | $-3.92M | $-17.13M | $-29.25M | $-14.26M | $-12.27M |
| Operating margin | — | — | — | — | — | — | — | — | — | -3.7% | -1.8% | -51.0% | -87.8% | -57.0% | -29.1% | -21.9% | -86.5% | -138.2% | -57.5% | -50.5% |
| EBITDA | $-407919.00 | $-407919.00 | $-997240.00 | $-475848.00 | $-1.27M | $-5.13M | $-280605.00 | $-94198.00 | $69499.00 | $-61076.00 | $-33407.00 | $-5.59M | $-4.54M | $-4.60M | $-1.24M | $-4.60M | $-12.27M | $-21.55M | $-23.22M | $-28.89M |
| EBITDA margin | — | — | — | — | — | — | — | — | — | -3.5% | -1.8% | -205.3% | -83.1% | -41.3% | -8.4% | -25.7% | -61.9% | -101.8% | -93.6% | -118.8% |
| EBIT | $-415366.00 | $-415366.00 | $-1.00M | $-478660.00 | $-1.27M | $-5.14M | $-282851.00 | $-95461.00 | $68101.00 | $-62118.00 | $-34230.00 | $-5.64M | $-5.00M | $-6.91M | $-4.81M | $-6.65M | $-16.12M | $-28.40M | $-29.03M | $-33.96M |
| Interest expense | $50178.00 | $3037.00 | — | $393.00 | $26143.00 | $3482.00 | $271.00 | $148.00 | $117.00 | $338.00 | $259.00 | $16775.00 | $84222.00 | $858323.00 | $736272.00 | $602372.00 | $85000.00 | $30000.00 | $19000.00 | $9914.00 |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-415365.00 | $-415365.00 | $-692989.00 | $-478661.00 | $-912033.00 | $-5.14M | $-283126.00 | $-95609.00 | $67988.00 | $-62463.00 | $-34494.00 | $-5.57M | $-5.20M | $-7.77M | $-5.18M | $-7.34M | $-17.09M | $-27.21M | $-26.43M | $-29.97M |
| Net income growth (YoY) | — | +0.0% | -66.8% | +30.9% | -90.5% | -463.0% | +94.5% | +66.2% | +171.1% | -191.9% | +44.8% | -16047.6% | +6.7% | -49.5% | +33.4% | -41.7% | -132.8% | -59.3% | +2.9% | -13.4% |
| Profit margin | — | — | — | — | — | — | — | — | — | -3.5% | -1.8% | -204.7% | -95.0% | -69.7% | -35.2% | -41.0% | -86.3% | -128.5% | -106.5% | -123.3% |